Prognostic Value of Preoperative Protein-induced Vitamin K Absence or Antagonist II After Liver Resection for Hepatitis B-related Hepatocellular Carcinoma: a Nationwide Multicenter Study

Overview

Journal Ann Surg Treat Res

Specialty General Surgery

Date 2022 Dec 1

PMID 36452307

Authors

Dahn Byun

Seul Gi Lee

Hyeyoung Kim

Yunghun You

Jaehag Jung

Je Ho Jang

Moon-Soo Lee

Chang-Nam Kim

Byung Sun Cho

Yoon-Jung Kang

Affiliations

Soon will be listed here.

Abstract

Purpose: Although protein-induced vitamin K absence or antagonist II (PIVKA-II) has been used as a diagnostic tool for hepatocellular carcinoma (HCC), its prognostic value remains unclear.

Methods: This was a nationwide multicenter study using the database of the Korean Liver Cancer Association. Patients with hepatitis B-related HCC who underwent liver resection as the first treatment after initial diagnosis (2008-2014) were selected randomly. Propensity score matching (1:1) was performed for comparative analysis between those with low and high preoperative PIVKA-II. Univariable and multivariable Cox proportional-hazards regression were used to identify prognostic factors for HCC-specific survival.

Results: Among 6,770 patients, 956 patients were included in this study. After propensity score matching, the 2 groups (n = 245, each) were well balanced. The HCC-specific 5-year survival rate was 80.9% in the low PIVKA-II group and 78.7% in the high PIVKA-II group (P = 0.605). In univariable analysis, high PIVKA-II (>106.0 mAU/mL) was not a significant predictor for worse HCC-specific survival (hazard ratio [HR], 1.183; 95% confidence interval [CI], 0.76-1.85; P = 0.461). In multivariable analysis, hyponatremia of <135 mEq/L (HR, 4.855; 95% CI, 1.67-14.12; P = 0.004), preoperative ascites (HR, 4.072; 95% CI, 1.59-10.43; P = 0.003), microvascular invasion (HR, 3.112; 95% CI, 1.69-5.74; P < 0.001), and largest tumor size of ≥5.0 cm (HR, 2.665; 95% CI, 1.65-4.31; P < 0.001), but not preoperative high PIVKA-II, were independent predictors for worse HCC-specific survival.

Conclusion: Preoperative PIVKA-II is not an independent prognostic factor for HCC-specific survival after liver resection for hepatitis B-related HCC.

References

Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S . Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003; 38(2):200-7. DOI: 10.1016/s0168-8278(02)00360-4. View

Kim H, Park J, Jang J, Kim H, Shin W, Kim K . Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. J Clin Gastroenterol. 2009; 43(5):482-8. DOI: 10.1097/MCG.0b013e318182015a. View

Kudo M, Takamine Y, Nakamura K, Shirane H, Uchida H, Kasakura S . Des-gamma-carboxy prothrombin (PIVKA-II) and alpha-fetoprotein-producing IIc-type early gastric cancer. Am J Gastroenterol. 1992; 87(12):1859-62. View

Llovet J, Pena C, Lathia C, Shan M, Meinhardt G, Bruix J . Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012; 18(8):2290-300. DOI: 10.1158/1078-0432.CCR-11-2175. View

Tsukamoto M, Nitta H, Imai K, Higashi T, Nakagawa S, Okabe H . Clinical significance of half-lives of tumor markers α-fetoprotein and des-γ-carboxy prothrombin after hepatectomy for hepatocellular carcinoma. Hepatol Res. 2017; 48(3):E183-E193. DOI: 10.1111/hepr.12942. View

Hong S, Lee K, Lee S, Hong S, Suh S, Han E . Impact of tumor size on hepatectomy outcomes in hepatocellular carcinoma: a nationwide propensity score matching analysis. Ann Surg Treat Res. 2022; 102(4):193-204. PMC: 9010965. DOI: 10.4174/astr.2022.102.4.193. View

Nkontchou G, Mahamoudi A, Aout M, Ganne-Carrie N, Grando V, Coderc E . Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology. 2009; 50(5):1475-83. DOI: 10.1002/hep.23181. View

Toyoda H, Kumada T, Kaneoka Y, Osaki Y, Kimura T, Arimoto A . Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol. 2008; 49(2):223-32. DOI: 10.1016/j.jhep.2008.04.013. View

Saito Y, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T . Prediction of recurrence of hepatocellular carcinoma after curative hepatectomy using preoperative Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein. Hepatol Res. 2012; 42(9):887-94. DOI: 10.1111/j.1872-034X.2012.01004.x. View

10.

. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69(1):182-236. DOI: 10.1016/j.jhep.2018.03.019. View

11.

Song P, Xia J, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N . Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol. 2016; 22(1):262-74. PMC: 4698491. DOI: 10.3748/wjg.v22.i1.262. View

12.

Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M . Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer. 2001; 91(3):561-9. DOI: 10.1002/1097-0142(20010201)91:3<561::aid-cncr1035>3.0.co;2-n. View

13.

Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N . Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol. 2011; 56(4):886-92. DOI: 10.1016/j.jhep.2011.10.021. View

14.

Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y . Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer. 2004; 101(4):796-802. DOI: 10.1002/cncr.20426. View

15.

Lim K, Chow P, Allen J, Chia G, Lim M, Cheow P . Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg. 2011; 254(1):108-13. DOI: 10.1097/SLA.0b013e31821ad884. View

16.

Imamura H, Matsuyama Y, Miyagawa Y, Ishida K, Shimada R, Miyagawa S . Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg. 1999; 86(8):1032-8. DOI: 10.1046/j.1365-2168.1999.01185.x. View

17.

Park H, Park J . Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma. Biomed Res Int. 2014; 2013:310427. PMC: 3885148. DOI: 10.1155/2013/310427. View

18.

Tang W, Kokudo N, Sugawara Y, Guo Q, Imamura H, Sano K . Des-gamma-carboxyprothrombin expression in cancer and/or non-cancer liver tissues: association with survival of patients with resectable hepatocellular carcinoma. Oncol Rep. 2004; 13(1):25-30. View

19.

Liebman H, Furie B, Tong M, BLANCHARD R, Lo K, Lee S . Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984; 310(22):1427-31. DOI: 10.1056/NEJM198405313102204. View

20.

Mazzaferro V, Sposito C, Zhou J, Pinna A, De Carlis L, Fan J . Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology. 2017; 154(1):128-139. DOI: 10.1053/j.gastro.2017.09.025. View